newsfilter
← Latest News
GlobeNewswire·

FDA Removes Partial Clinical Hold on MacroGenics' LINNET Study

• Plan to resume enrollment in clinical study of lorigerlimab in gynecologic cancers • On track to provide mid-2026 program update ROCKVILLE, MD, April 08, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX),